Meeting
2019 ASCO Annual Meeting
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
Authors
Jay Y. Spiegel
Stanford University, Stanford, CA
Jay Y. Spiegel , Saurabh Dahiya , Michael D. Jain , Loretta J. Nastoupil , Armin Ghobadi , Yi Lin , Matthew Alexander Lunning , Patrick Michael Reagan , Joseph McGuirk , Abhinav Deol , Javier Munoz , Frederick Lundry Locke , Sattva Swarup Neelapu , John S Tamaresis , Aaron Rapoport , David Bernard Miklos , Brian Thomas Hill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7517)
DOI
10.1200/JCO.2019.37.15_suppl.7517
Abstract #
7517
Poster Bd #
271
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke
Poster
2022 ASCO Annual Meeting
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
First Author: Frederick L. Locke
Poster
2021 ASCO Annual Meeting
Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.
First Author: Henan Zhang